LataMed AI Corp. (OTC: LMEDD) announced today that its 5-for-1 forward stock split has become effective, marking a key milestone in the company's capital structure strategy. The split, which was previously announced, took effect at the opening of trading following the publication of the corporate action on the FINRA Daily List dated July 14, 2026.
As a result of the forward stock split, the company's common stock will trade under the temporary symbol LMEDD. The 'D' designation, a standard identifier used by FINRA for certain corporate actions, is expected to remain in place for approximately 20 business days before reverting to the original symbol LMED. The split is also accompanied by a mandatory share exchange and a new CUSIP number, 21116R404, while the prior CUSIP, 21116R305, has been suspended.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., emphasized the strategic importance of the move: 'Today's implementation of our forward stock split represents an important corporate milestone for LataMed AI. We appreciate the continued support of our shareholders and look forward to continuing the execution of our long-term strategy as we focus on expanding our telemedicine platform and pursuing commercialization opportunities for our CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms.'
The forward stock split is designed to increase the number of outstanding shares, potentially enhancing liquidity and making the stock more accessible to a broader range of investors. For shareholders holding shares through brokerage accounts or in electronic book-entry form, no action is required, as the corporate action will be processed automatically through the normal securities settlement process. Those holding physical stock certificates are not required to immediately surrender them, but when presented for transfer, sale, or exchange, they will be processed under the new CUSIP.
LataMed AI Corp. is a development-stage digital health and artificial intelligence technology company focused on building telehealth infrastructure and AI-enabled healthcare solutions for emerging markets. The company's strategy centers on developing platforms to support healthcare access, patient engagement, provider coordination, and data-driven operations, with an initial focus on Latin America. The forward stock split aligns with the company's efforts to pursue commercialization opportunities for its AI platforms, including CardioAI, PulmoAI, and NeuroAI.
Investors and shareholders with questions regarding the exchange process are encouraged to contact their brokerage firm or the company's transfer agent. Additional information is available on the company's website at https://latamed.ai and through its filings with the U.S. Securities and Exchange Commission at www.sec.gov.
This press release contains forward-looking statements regarding the company's business strategy, corporate actions, and operational execution. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. The company undertakes no obligation to update these statements except as required by law.
